Blog
BeCytes Biotechnologies
. New Alternative Models (NAMs) for research, which include in vitro cellular models, are destined to transform the future of biomedical research. Regulatory agencies implement laws concerning animal use [...]
Published On: 19/06/2024-
Metabolic (dysfunction) associated fatty liver disease (MAFLD) is the most common chronic liver disease, affecting around 25 % of the world population. It is characterized by an accumulation of [...]
Published On: 12/06/2024 -
Liver models to test new drugs based on 2D cell culture of primary hepatocytes and the use of experimental animal models are slow, costly, and have significant biases. BeCytes [...]
Published On: 27/05/2024 -
Drug-induced liver injury (DILI) has fatal consequences, both personally and economically. Its health impact ranges from mild liver enzyme elevation to severe liver failure. In the drug development process, [...]
Published On: 10/05/2024 -
Regulatory agencies, such as the Food and Drug Administration (FDA), are moving towards reducing animal testing and encouraging the use of New Alternative Methodologies (NAMs) in pharmaceutical research. NAMs [...]
Published On: 15/04/2024 -
Experts talks: In vitro liver models for reliable predictions in preclinical stages The advent of new alternative methodologies marks a significant stride forward in biomedical research, enabling safer and [...]
Published On: 03/04/2024
